Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening

CA Cancer Journal for Clinicians

Volumn 66, Issue 2, 2016, Pages 95-114

  Smith, Robert A ^a   Andrews, Kimberly ^a   Brooks, Durado ^a   Desantis, Carol E ^a   Fedewa, Stacey A ^a   Lortet Tieulent, Joannie ^a   Manassaram Baptiste, Deana ^a   Brawley, Otis W ^a   Wender, Richard C ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

breast neoplasms; cervical neoplasms; colon and rectum neoplasms; early detection; lung neoplasms; screening

Indexed keywords

BRCA1 PROTEIN; CA 125 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; WART VIRUS VACCINE;

AGE DISTRIBUTION; BARIUM ENEMA; BREAST CANCER; BREAST EXAMINATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CAUSE OF DEATH; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; DECISION MAKING; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; FAMILY HISTORY; HEALTH CARE PERSONNEL; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; LUNG CANCER; MAMMOGRAPHY; MEDICAL SOCIETY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD; OVARY CANCER; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIGMOIDOSCOPY; SMOKING; UNITED STATES; UTERINE CERVIX CANCER; WART VIRUS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; FEMALE; HEALTH SURVEY; LUNG NEOPLASMS; MALE; NEOPLASMS; NON PROFIT ORGANIZATION; OVARIAN NEOPLASMS; PREVALENCE; PROCEDURES; PROSTATIC NEOPLASMS; STANDARDS; UTERINE NEOPLASMS;

AMERICAN CANCER SOCIETY; BREAST NEOPLASMS; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GUIDELINES AS TOPIC; HUMANS; LUNG NEOPLASMS; MALE; MAMMOGRAPHY; NEOPLASMS; OVARIAN NEOPLASMS; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; PREVALENCE; PROSTATIC NEOPLASMS; UNITED STATES; UTERINE NEOPLASMS;

EID: 84960799406     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21336     Document Type: Review

References (100)

1. Brawley O, Byers T, Chen A, et al., New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA. 2011; 306: 2495-2499.
2. Smith RA, Cokkinides V, Brawley OW., Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2012; 62: 129-142.
3. Smith RA, Saslow D, Sawyer KA, et al., American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003; 53: 141-169.
4. Saslow D, Boetes C, Burke W, et al., American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007; 57: 75-89.
5. Oeffinger KC, Fontham ET, Etzioni R, et al., Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015; 314: 1599-1614.
6. Saslow D, Runowicz CD, Solomon D, et al., American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342-362.
7. Saslow D, Castle PE, Cox JT, et al., American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007; 57: 7-28.
8. Saslow D, Solomon D, Lawson HW, et al., American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62: 147-172.
9. Smith RA, Manassaram-Baptiste D, Brooks D, et al., Cancer screening in the United States, 2015: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015; 65: 30-54.
10. Smith RA, von Eschenbach AC, Wender R, et al., American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001-testing for early lung cancer detection. CA Cancer J Clin. 2001; 51: 38-75; quiz 77-80.
11. Levin B, Brooks D, Smith RA, Stone A., Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003; 53: 44-55.
12. Rex DK, Kahi CJ, Levin B, et al., Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin. 2006; 56: 160-167; quiz 185-166.
13. Winawer SJ, Zauber AG, Fletcher RH, et al., Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin. 2006; 56: 143-159; quiz 184-145.
14. Levin B, Lieberman DA, McFarland B, et al., Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008; 58: 130-160.
15. Wolf AM, Wender RC, Etzioni RB, et al., American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010; 60: 70-98.
16. American Cancer Society. American Cancer Society Lung Cancer Guidance Workgroup. Interim guidance on lung cancer screening. Atlanta, GA: American Cancer Society; 2011. cancer.org/Healthy/FindCancerEarly/index. Accessed September 24, 2011.
17. Wender R, Fontham ET, Barrera E Jr, et al., American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013; 63: 107-117.
18. Howlander N, Noone A, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2012. Bethesda, MD: National Cancer Institute; 2015.
19. Siegel RL, Miller KD, Jemal A., Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: xx-xx.
20. Samson D, Schoelles KM., Chapter 2. Developing the topic and structuring systematic reviews of medical tests: utility of PICOTS, analytic frameworks, decision trees, and other frameworks. In: Chang SM, Matchar DB, Smetana GW, Umscheid CA, eds. Methods Guide for Medical Test Reviews. AHRQ Publication No. 12-EC017. Rockville, MD: Center for Outcomes and Effectiveness, Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services; 2012:2-1-2-12.
21. Myers ER, Moorman P, Gierisch JM, et al., Benefits and harms of breast cancer screening: a systematic review. JAMA. 2015; 314: 1615-1634.
22. Miglioretti DL, Zhu W, Kerlikowske K, et al., Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. JAMA Oncol. 2015; 1: 1069-1077.
23. Tabar L, Yen AM, Wu WY, et al., Insights from the breast cancer screening trials: how screening affects the natural history of breast cancer and implications for evaluating service screening programs. Breast J. 2015; 21: 13-20.
24. Guyatt G, Oxman AD, Akl EA, et al., GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64: 383-394.
25. Atkins D, Best D, Briss PA, et al., Grading quality of evidence and strength of recommendations [serial online]. BMJ. 2004; 328: 1490.
26. Andrews J, Guyatt G, Oxman AD, et al., GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013; 66: 719-725.
27. Andrews JC, Schunemann HJ, Oxman AD, et al., GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol. 2013; 66: 726-735.
28. American College of Obstetricians-Gynecologists. Practice bulletin no. 122: breast cancer screening. Obstet Gynecol. 2011; 118: 372-382.
29. US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 151: 716-726, W-236.
30. Tabar L, Fagerberg G, Chen HH, et al., Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer. 1995; 75: 2507-2517.
31. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A., Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer. 1996; 66: 413-419.
32. White E, Miglioretti DL, Yankaskas BC, et al., Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Inst. 2004; 96: 1832-1839.
33. Buist DS, Porter PL, Lehman C, Taplin SH, White E., Factors contributing to mammography failure in women aged 40-49 years. J Natl Cancer Inst. 2004; 96: 1432-1440.
34. Kerlikowske K, Zhu W, Hubbard RA, et al., Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med. 2013; 173: 807-816.
35. O'Meara ES, Zhu W, Hubbard RA, et al., Mammographic screening interval in relation to tumor characteristics and false-positive risk by race/ethnicity and age. Cancer. 2013; 119: 3959-3967.
36. Gold EB, Crawford SL, Avis NE, et al., Factors related to age at natural menopause: longitudinal analyses from SWAN. Am J Epidemiol. 2013; 178: 70-83.
37. Lee SJ, Smith AK, Widera EW, Yourman LC, Schonberg MA, Ahalt C., Eprognosis: Estimating prognosis for elders. Division of Geriatrics at the University of California San Francisco. eprognosis.org. Accessed September 29, 2015.
38. Walter LC, Schonberg MA., Screening mammography in older women: a review. JAMA. 2014; 311: 1336-1347.
39. Anderson BO, Yip CH, Smith RA, et al., Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer. 2008; 113: 2221-2243.
40. Smith RA, Cokkinides V, Eyre HJ., American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin. 2003; 53: 27-43.
41. Austoker J, Bankhead C, Forbes LJ, et al., Interventions to promote cancer awareness and early presentation: systematic review. Br J Cancer. 2009; 101 (suppl 2): S31-S39.
42. Orom H, Kiviniemi MT, Underwood W 3rd, Ross L, Shavers VL., Perceived cancer risk: why is it lower among nonwhites than whites? Cancer Epidemiol Biomarkers Prev. 2010; 19: 746-754.
43. Malmgren JA, Parikh J, Atwood MK, Kaplan HG., Impact of mammography detection on the course of breast cancer in women aged 40-49 years. Radiology. 2012; 262: 797-806.
44. Ewertz M, Jensen AB., Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol. 2011; 50: 187-193.
45. American Cancer Society. Breast Cancer Screening Guidelines. Atlanta, GA: American Cancer Society; 2014. cancer.org/healthy/informationforhealthcareprofessionals/acsguidelines/breastcancerscreeningguidelines/index. Accessed October 10, 2014.
46. Tosteson AN, Fryback DG, Hammond CS, et al., Consequences of false-positive screening mammograms. JAMA Intern Med. 2014; 174: 954-961.
47. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M., The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013; 108: 2205-2240.
48. Office for Public Management. Citizens' Jury on Information for Women About Breast Screening: Report to Informed Choice About Cancer Screening. London, UK: Office of Public Management; 2012.
49. Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ., Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat. 2009; 115: 381-390.
50. Gail MH, Mai PL., Comparing breast cancer risk assessment models. J Natl Cancer Inst. 2010; 102: 665-668.
51. Gail MH., Twenty-five years of breast cancer risk models and their applications [serial online]. J Natl Cancer Inst. 2015; 107: djv042.
52. Claus EB, Risch N, Thompson WD., Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994; 73: 643-651.
53. Tyrer J, Duffy SW, Cuzick J., A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004; 23: 1111-1130.
54. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al., BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002; 20: 2701-2712.
55. Chen S, Parmigiani G., Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25: 1329-1333.
56. Antoniou AC, Pharoah PP, Smith P, Easton DF., The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer. 2004; 91: 1580-1590.
57. Gail MH, Brinton LA, Byar DP, et al., Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81: 1879-1886.
58. Ozanne EM, Drohan B, Bosinoff P, et al., Which risk model to use? Clinical implications of the ACS MRI screening guidelines. Cancer Epidemiol Biomarkers Prev. 2013; 22: 146-149.
59. Moyer VA., Screening for cervical cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156: 880-891, W312.
60. Huh WK, Ault KA, Chelmow D, et al., Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015; 136: 178-182.
61. Petrosky E, Bocchini JA Jr, Hariri S, et al., Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015; 64: 300-304.
62. Markowitz LE, Dunne EF, Saraiya M, et al., Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014; 63: 1-30.
63. Reagan-Steiner S, Yankey D, Jeyarajah J, et al., National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2014. MMWR Morb Mortal Wkly Rep. 2015; 64: 784-792.
64. Centers for Disease Control (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR Morb Mortal Wkly Rep. 2013; 62: 591-595.
65. Siegel R, Desantis C, Jemal A., Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 104-117.
66. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR., Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012; 143: 844-857.
67. Collins JF, Lieberman DA, Durbin TE, Weiss DG., Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005; 142: 81-85.
68. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM., Evaluating test strategies for colorectal cancer screening: a decision analysis for the US Preventive Services Task Force. Ann Intern Med. 2008; 149: 659-669.
69. Shaukat A, Mongin SJ, Geisser MS, et al., Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013; 369: 1106-1114.
70. Winawer S, Fletcher R, Rex D, et al., Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003; 124: 544-560.
71. Giardiello FM, Allen JI, Axilbund JE, et al., Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014; 109: 1159-1179.
72. Millan MS, Gross P, Manilich E, Church JM., Adenoma detection rate: the real indicator of quality in colonoscopy. Dis Colon Rectum. 2008; 51: 1217-1220.
73. Cotton PB, Connor P, McGee D, et al., Colonoscopy: practice variation among 69 hospital-based endoscopists. Gastrointest Endosc. 2003; 57: 352-357.
74. Rex DK, Petrini JL, Baron TH, et al., Quality indicators for colonoscopy. Gastrointest Endosc. 2006; 63: S16-S28.
75. Lieberman D, Nadel M, Smith RA, et al., Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc. 2007; 65: 757-766.
76. Rex DK, Schoenfeld PS, Cohen J, et al., Quality indicators for colonoscopy. Am J Gastroenterol. 2015; 110: 72-90.
77. Pohl H, Robertson DJ., Colorectal cancers detected after colonoscopy frequently result from missed lesions. Clin Gastroenterol Hepatol. 2010; 8: 858-864.
78. Singh H, Nugent Z, Demers AA, Bernstein CN., Rate and predictors of early/missed colorectal cancers after colonoscopy in Manitoba: a population-based study. Am J Gastroenterol. 2010; 105: 2588-2596.
79. Corley DA, Jensen CD, Marks AR, et al., Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014; 370: 1298-1306.
80. Kaminski MF, Regula J, Kraszewska E, et al., Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010; 362: 1795-1803.
81. Fletcher RH, Nadel MR, Allen JI, et al., The quality of colonoscopy services-responsibilities of referring clinicians: a consensus statement of the Quality Assurance Task Group, National Colorectal Cancer Roundtable. J Gen Intern Med. 2010; 25: 1230-1234.
82. Walker JL, Nunez ER., Endometrial cancer. In:, Kramer BS, Gohagan JK, Prorok PC, eds. Cancer Screening: Theory and Practice. New York: Marcel Dekker, Inc; 1999: 531-566.
83. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al., Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.
84. Bach PB, Mirkin JN, Oliver TK, et al., Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012; 307: 2418-2429.
85. Moyer VA, US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160: 330-338.
86. US Centers for Medicare and Medicaid Services. Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N). Centers for Medicare and Medicaid Services. cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274. Accessed October 15, 2015.
87. Johnson CC, Kessel B, Riley TL, et al., The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol. 2008; 110: 383-389.
88. Duffy MJ, Bonfrer JM, Kulpa J, et al., CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005; 15: 679-691.
89. Moss EL, Hollingworth J, Reynolds TM., The role of CA125 in clinical practice. J Clin Pathol. 2005; 58: 308-312.
90. Fishman DA, Cohen L, Blank SV, et al., The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol. 2005; 192: 1214-1221; discussion 1221 -1212.
91. Ren J, Cai H, Li Y, et al., Tumor markers for early detection of ovarian cancer. Expert Rev Mol Diagn. 2010; 10: 787-798.
92. Kobayashi E, Ueda Y, Matsuzaki S, et al., Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1902-1912.
93. Summaries for patients. Screening for ovarian cancer: US Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2012; 157: 1-56.
94. Menon U, Gentry-Maharaj A, Hallett R, et al., Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10: 327-340.
95. Jacobs I, Menon U, Ryan A, et al., Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2015: 1-12.
96. National Institutes of Health (NIH). Ovarian Cancer: Screening, Treatment, and Follow-Up. NIH Consensus Statement. Bethesda, MD: NIH; 1994.
97. Daly MB, Axilbund JE, Berry M, et al., NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2015. Fort Washington, PA: National Comprehensive Cancer Network; 2015.
98. Doria-Rose VP, White MC, Klabunde CN, et al., Use of lung cancer screening tests in the United States: results from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1049-1059.
99. Dahlhamer JM, Simile CM., Subunit Nonresponse in the National Health Interview Survey (NHIS): An Exploration Using Paradata. American Statistical Association. amstat.org/sections/srms/proceedings/y2009/Files/302933.pdf. Accessed October 3, 2015.
100. Rauscher GH, Johnson TP, Cho YI, Walk JA., Accuracy of self-reported cancer-screening histories: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008; 17: 748-757.